Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 4/20 | 0.37 |
| ▸ | MAOA | P21397 | 1/20 | 0.33 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.33 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.33 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.33 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.33 |
| ▸ | ESR1 | P03372 | 1/20 | 0.32 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.32 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.32 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.32 |
| ▸ | ACACB | O00763 | 1/20 | 0.32 |
| ▸ | AKR1C3 | P42330 | 3/20 | 0.32 |
| ▸ | AKR1C2 | P52895 | 3/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL116107 | 0.81 | ALOX5 (0.37) | SLC6A4FOLH1ALOX5ACACBAKR1C3 | |
| SCHEMBL14473162 | 0.79 | ESR1 (0.41) | SLC6A4MAOASLC6A2SLC6A3ALOX5 | |
| SCHEMBL115613 | 0.78 | SLC6A4 (0.37) | SLC6A4FOLH1ALOX5AKR1C3AKR1C2 | |
| SCHEMBL1713352 | 0.77 | — | — | |
| SCHEMBL115612 | 0.76 | SLC6A4 (0.44) | SLC6A4MAOASLC6A2SLC6A3ALOX5 | |
| SCHEMBL12204725 | 0.76 | ALDH1A1 (0.40) | SLC6A4SLC6A2ALOX5ACACB | |
| SCHEMBL114972 | 0.74 | AKR1C3 (0.33) | SLC6A4ESR1PDCD1ESR2CD274 | |
| SCHEMBL17753549 | 0.74 | FOLH1 (0.33) | FOLH1 | |
| SCHEMBL115662 | 0.74 | SLC6A4 (0.40) | SLC6A4MAOASLC6A2SLC6A3 | |
| SCHEMBL29790356 | 0.74 | CYP2A6 (0.38) | FOLH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2424859-B1 | INHIBITORS OF PI3 KINASE AND / OR MTOR | AMGEN INC (US) | 2015-04-08 | — | — | EP | disclosed |
| US-8772480-B2 | Inhibitors of PI3 kinase and/or mTOR | AMGEN INC. (US) | 2014-07-08 | — | — | US | disclosed |
| US-20130079303-A1 | Inhibitors of PI3 Kinase and/or mTOR | AMGEN INC. (US) | 2013-03-28 | — | — | US | disclosed |
| US-8362241-B2 | Inhibitors of PI3 kinase and/or mTOR | AMGEN INC. (US) | 2013-01-29 | — | — | US | disclosed |
| EP-2424859-A1 | INHIBITORS OF PI3 KINASE AND / OR MTOR | Amgen, Inc (US) | 2012-03-07 | — | — | EP | disclosed |
| WO-2010126895-A1 | INHIBITORS OF PI3 KINASE AND / OR MTOR | AMGEN INC. (US) | 2010-11-04 | — | — | WO | disclosed |
| US-20100273764-A1 | INHIBITORS OF PI3 KINASE AND/OR MTOR | AMGEN INC. (US) | 2010-10-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100273764-A1 | INHIBITORS OF PI3 KINASE AND/OR MTOR | MTOR, PIK3CA, PIK3CD | SLC6A4 2196/4885MAOA 4648/4885SLC6A2 2158/4885 |
| US-20130079303-A1 | Inhibitors of PI3 Kinase and/or mTOR | MTOR, PIK3CA, PIK3CD | SLC6A4 2196/4885MAOA 4648/4885SLC6A2 2158/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.